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ABSTRACT
Objectives To evaluate the effectiveness of integrated
motivational interviewing and cognitive behavioural
therapy in addition to standard care for patients with
psychosis and a comorbid substance use problem.
Design Two centre, open, rater blind randomised
controlled trial.
Setting Secondary care in the United Kingdom.
Participants 327 patients with a clinical diagnosis of
schizophrenia, schizophreniform disorder, or
schizoaffective disorder and a diagnosis of dependence
on or misuse of drugs, alcohol, or both according to the
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition.
Intervention The interventionwas integratedmotivational
interviewing and cognitive behavioural therapy plus
standard care, which was compared with standard care
alone. Phase one of therapy—“motivation building”—
concerns engaging the patient, then exploring and
resolving ambivalence for change in substance use.
Phase two—“action”—supports and facilitates change
using cognitive behavioural approaches. Up to 26 therapy
sessions were delivered over one year.
Main outcomemeasures The primary outcome was death
from any cause or admission to hospital in the 12months
after completion of therapy. Secondary outcomes were
frequency and amount of substance use (assessed using
the timeline followback method), readiness to change,
perceived negative consequences of use, psychotic
symptom ratings, number and duration of relapses, and
global assessment of functioning and deliberate self
harm at 12 and 24 months, with additional timeline
followback assessments at 6 and 18 months. Analysis
was by intention to treat and robust treatment effect
estimates were produced.
Results 327 participants were randomly allocated to
either the intervention (n=164) or treatment as usual
(n=163). At 24 months, 326 (99.7%) were assessed on
the primary outcome and 246 (75.2%) on the main
secondary outcomes. Treatment had no beneficial effect
on hospital admissions or death during follow-up, with
23.3% (38/163) of the therapy group and 20.2% (33/
163) of controls deceased or admitted (adjusted odds
ratio 1.16, 95% confidence interval 0.68 to 1.99;
P=0.579). Therapy had no effect on the frequency of
substance use or the perceived negative consequences of
misuse, but did have a statistically significant effect on
amount used per substance using day (adjusted ORs for
main substance 1.50, 95% CI 1.08 to 2.09; P=0.016; and
all substances 1.48, 95% CI 1.07 to 2.05; P=0.017).
Treatment had a statistically significant effect on
readiness to change use at 12 months (adjusted OR 2.05,
95% CI 1.26 to 3.31; P=0.004) that was not maintained at
24 months (0.78, 95% CI 0.48 to 1.28; P=0.320). There
were no effects of treatment on clinical outcomes such as
relapses, psychotic symptoms, functioning, and self
harm.
Conclusions Integrated motivational interviewing and
cognitive behavioural therapy for people with psychosis
and substance misuse do not improve outcome in terms
of hospitalisation, symptom outcomes, or functioning.
This approach does reduce the amount of substance used
for at least one year after completion of therapy.
Trial registration Current Controlled Trials:
ISRCTN14404480.
INTRODUCTION
People with psychosis have much higher rates of pro-
blem alcohol and illicit drug use than the general popu-
lation. The United States Epidemiologic Catchment
Area study calculated that the odds of having an alcohol
or drug disorder for people with a diagnosis of schizo-
phrenia were three and six times higher than for the
general population, respectively.1 In the United King-
dom, the prevalence of co-occurring substance misuse
in past year amongpeoplewith psychosis is estimated at
around 25%.23 These dual problems are associated
with many illness complications, including increased
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severity of symptoms, suicide, poorer compliance with
treatment, non-adherence tomedication, more hospita-
lisations, violence, homelessness, and victimisation.45
ACochrane reviewof psychosocial interventions for
people with both severe mental illness and substance
misuse identified 25 studies.6 The authors concluded
that there is no compelling evidence to support any
one psychosocial treatment to reduce substance use
or to improve mental state in this patient group. They
also identified major problems in the studies con-
ducted, including small heterogeneous samples,
flawed experimental designs, high attrition rates, and
short follow-up periods.
Although the evidence base is limited, key elements
have been recommended for treatments that aim to
reduce substance use and thereby improve
outcomes.78 These include, firstly, ensuring that both
mental health and substance use problems are given
attention in an integrated approach and, secondly,
addressing patients’ motivation to reduce substance
use. Given that motivation to reduce substance use is
often low in such patients,910 motivational inter-
ventions, and in particular motivational interviewing,11
have also been recommended. Motivational inter-
viewing has a good evidence base with regard to
promoting health behaviour change,12 including in
treatment for substance misuse.13 An additional
approach commonlyused is cognitivebehavioural ther-
apy, because it is efficacious for both primary substance
misuse disorders14-16 and psychotic symptoms.1718
We have previously reported a small sample size ran-
domised controlled trial that evaluated a nine month
individual treatment consisting of motivational inter-
viewing plus individual and family cognitive beha-
vioural therapy for patients with schizophrenia and
comorbid substancemisuse.1019At 12months, the treat-
ment was superior to standard care provided bymental
health services in terms of patients’ general functioning,
positive symptoms (excess or distortion of normal func-
tioning, such as delusion and hallucinations), symptom
exacerbations, and frequency of substance use. Some
gains were lost at the 18 month follow-up, although
improvement in general functioning was maintained
and the experimental group showed improvednegative
symptoms (diminution or loss of normal functions, such
as affective flattening, anhedonia, and attentional
impairment) at 18 months.
We aimed to conduct a full scale randomised con-
trolled trial to determine the efficacy of integrated
motivational interviewing and cognitive behavioural
therapy delivered by trained therapists in addition to
mental health services standard care. On the basis of
the findings of our previous study, a numberof changes
were made to the therapy and study design. For exam-
ple, there was increased emphasis on facilitating moti-
vation, given the low levels ofmotivation for change in
our first study. To increase the generalisability of our
findings, the study includedpatientswithout carers and
therefore excluded the family component of the inter-
vention. The treatment period was extended to
12 months to allow more time for patients to
participate in therapy, given that the lifestyles of
someparticipantsmade regular appointments difficult,
missed appointments inevitable, and periods of disen-
gagement common.
METHODS
The trial was overseen by independent data monitor-
ing and trial steering committees and is reported
in accordance with the CONSORT guidelines for
non-pharmacological trials.20-22 Ethical approval was
obtained from the Cambridgeshire 4 research ethics
committee (formerly the eastern multicentre research
ethics committee; reference 03/5/045). All participants
gave written informed consent before taking part.
Participants
BetweenOctober 2004 and April 2007 research teams
in two centres (Manchester andLondon) recruited par-
ticipants from adult services in six large NHS mental
health trusts in the UK covering Greater Manchester,
Lancashire, and south London. Inclusion criteria were
the following: age more than 16 years; in current con-
tact withmental health services; a current clinical diag-
nosis of non-affective psychotic disorder (international
classification of diseases, 10th revision (ICD-10),Diag-
nostic and Statistical Manual of Mental Disorders, fourth
edition (DSM-IV), or both); DSM-IV diagnosis of
dependence on or abuse of drugs, alcohol, or both;
minimum level of weekly alcohol use (exceeding 28
units for males and 21 units for females on at least
half the weeks in the past three months) or illicit drug
use (use on at least two days a week in at least half the
weeks in the past three months); no significant history
of organic factors implicated in the aetiology of psy-
chotic symptoms; English speaking; and of a fixed
abode (including bed and breakfast or hostel).
Procedure
Potential participantswere identified by care coordina-
tors.Where case notes confirmeddiagnostic eligibility,
a research assistant askedpotential participants to com-
plete a checklist of substances used anddescribe typical
alcohol anddrugs use in the past threemonths. Patients
meeting inclusion criteria for levels of alcohol use, illi-
cit drug use, or both completed the alcohol and drug
sections of the structured clinical interview for the
DSM-IV, as appropriate.23 If patients used more than
one illicit drug, the assessment was administered for
the drug perceived by the participant to be most pro-
blematic or, if the person did not make such a distinc-
tion, the most frequently used. If dependence or abuse
criteria were not met for this drug, the assessment was
repeated for the next most problematic drug until cri-
teria were met. Those not meeting DSM-IV depen-
dence or abuse criteria for alcohol or an illicit drug
were not eligible to participate in the trial.
After screening, participants were assessed for base-
linemeasures. Randomallocation to therapy plus stan-
dard care or standard care alonewas performedusing a
remote independent service, with aminimisation algo-
rithm taking into account substance type (alcohol
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alone, drugs alone, or alcohol and drugs), main drug of
use (cannabis, amphetamines, opiates, or other), and
NHS trust.
Intervention
The psychological therapy consisted of up to 26 indi-
vidual therapy sessions delivered over 12 months at
the patient’s location of choice, which was usually
their home. Where patients consented, therapy ses-
sions were audiotaped for therapist supervision and
evaluation of treatment fidelity. The therapywas deliv-
ered in accordance with the detailed manual, available
from the corresponding author and described
elsewhere.24
Considerable emphasis was placed on initiating and
maintaining engagement in therapy with strategies
such as brief initial visits with conversation based on
the patient’s interests for those reluctant to engage;
identifying lifestyle change as the key therapy target
so as not to engender resistance in those with lowmoti-
vation to reduce substance use in the initial stages of the
intervention; rescheduling of missed appointments;
flexibility in timing and location of sessions; and track-
ing of change in residence.
Treatment was built around two phases to allow
motivational interviewing and cognitive behavioural
therapy to be integrated without compromising the
essential spirit and fundamentals of each approach.
Phase one of the intervention—“motivation build-
ing”—selectively elicited and reinforced “change
talk” through use of the core skills and principles of
motivational interviewing.11 The following stages
were used: engagement; eliciting and understanding
the patient’s perspective in relation to life goals; and
exploring the patient’s perspectives on both substance
misuse and mental health issues in relation to goals.
Information and feedback fromassessments was incor-
porated into these stages using a motivational style to
support formulation of a shared understanding in rela-
tion to the person’s concerns, substance misuse, and
mental health difficulties. This was used to further
develop ambivalence and consolidate motivation for
changing substance use.
In phase two of the intervention, a plan for change
was developed. Where the person was open to change
in substance use, cognitive behavioural techniques
from both the psychosis and substance use evidence
base were used to formulate a change plan and to
help the patient implement and maintain changes
such as reduction or abstinence in one or more sub-
stances.Components included identifying and increas-
ing awareness of high risk situations and warning signs
for substance use lapse or relapse; developing coping
skills for handling such situations,with particular atten-
tion to psychosis symptoms and mental health pro-
blems highlighted in formulation (for example,
strategies for dealing with distressing voices or with
depressed mood); coping with cravings and urges;
making lifestyle changes as alternatives to substance
use; and normalising and responding to lapses and
relapses. For those who did not identify substance use
as problematic, the intervention was sufficiently flex-
ible to allow therapists to work with other patient led
problems. In such cases, the therapist would use moti-
vational interviewing techniques to help the patient to
link substance use to their concerns. Three liaison
meetings between the patient, the therapist, and the
patient’s case manager were scheduled during therapy
to communicate progress.
Standard psychiatric care in the UK comprises anti-
psychotic medication, outpatient and community
follow-up, and access to community based rehabilita-
tive activities. To reduce variation among the clinical
teams with regard to access to substance misuse ser-
vices, we provided a handbook containing brief guide-
lines on managing people with psychosis and
substance misuse, including information on medica-
tion and a directory of local resources.
Training and monitoring trial therapists
The trial therapistswere two clinical psychologists, two
nurse therapists, and one social worker, who all had
training and experience in conducting cognitive beha-
vioural therapy with people who have psychosis. Dur-
ing a three month period before seeing trial
participants, therapists undertook training in motiva-
tional interviewing, cognitive behavioural therapy for
substance misuse, and integrated motivational inter-
viewing and cognitive behavioural therapy, with all
therapists practising the integrated therapywith volun-
teer patients under supervision. Weekly group and
individual supervision were provided while the thera-
pists were treating trial participants.
Treatment fidelity and quality were assessed in
supervision via listening to the therapy audiotapes
and discussion of cases, with frequent reference to the
therapy manual. Additionally, an independent rater
with experience in delivering motivational inter-
viewing and cognitive behavioural therapy assessed a
sample of 40 audiotaped therapy sessions, each from a
different participant, that were randomly selected from
the pool of 1248 audiotaped sessions. The rater used a
fidelity scale designed to assess integratedmotivational
interviewing and cognitive behavioural therapy.25 This
scale consists of 16 items, each rated as “compliant” or
“not compliant,” that were generated from the treat-
ment protocol and used to facilitate assessment of ther-
apy content and structure, and the core skills of the
therapist. The scale has good inter-rater reliability
and validity.
Assessment of outcomes
Demographic information and duration of psychosis
and substance misuse were collected at baseline via
self report. The alcohol use disorders identification
test26 27 and the drug misuse screening test28 29 assessed
severity of use. The drug attitude inventorywas used as
a proxy measure for compliance with prescribed anti-
psychotic medication.30
For outcomes requiring self reports, research assis-
tants blind to treatment allocation assessed participants
at baseline, after completion of treatment (12 months),
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andone year after completion of treatment (24months),
with two additional assessment points at six and
18months for evaluation of substance use (timeline fol-
lowback). Precautionswere taken tomaintain the blind-
ness of the study; for example, research and therapy
staff were located in separate offices, assessment and
therapy data were stored separately, appointments
were managed by a third party in order to avoid
appointment clashes, and patients and care coordina-
torswere remindedbefore andat the start of each assess-
ment not to give information that might “unblind” the
assessor. Throughout the trial, 135 breaks in the blind-
ness of an assessor were reported in total. However,
only one assessment was completed unblinded; in all
other cases a new “blind” assessor was allocated.
Primary outcome
The primary outcome for the trial was admission to
hospital for a reason related to psychosis or death
from any cause, versus not admitted to hospital and
alive in the 12 month post-treatment period. Data
were obtained from participant psychiatric case
notes. Admissions made specifically for a pre-planned
change of medication were not counted.
Secondary outcomes: relapses and admissions
Case notes were also used to assess frequency and
duration of hospital admissions and relapses in the
year before the trial and during the two year trial per-
iod. Relapse was defined as an exacerbation of psycho-
tic symptoms that lasted longer than two weeks and
required a change in patient management (medication
change, increased observation by the clinical team
(including hospitalisation), or both). For each partici-
pant, dates of every admission and discharge, and the
start and end of each period of relapse, were recorded,
as well as verbatim extractions from the notes describ-
ing changes in symptoms and management.
Before assessing participant notes, research assis-
tants were trained to protocol then extracted data
from a set of six test cases and rated admissions and
relapses. Inter-rater reliability across all assessors was
excellent,31 with the following mean intraclass correla-
tion coefficients: admission (yes/no) 0.98; number of
admissions 0.93; weeks in admission 0.82; relapse
(yes/no) 0.87; and number of relapses 0.85. Regular
supervision anddata checkingwere provided to ensure
consistency and adherence to protocol.
Secondary outcomes: substance use
The readiness to change questionnaire32 and the inven-
tory of drug use consequences33 were used to assess
motivation to change substance misuse and perceived
negative consequences of misuse, respectively. Fre-
quency andquantity of substancemisusewere assessed
using the timeline followback method,34 which has
good reported reliability and validity in dual diagnosis
populations.35-37 The timeline followback procedure
reconstructs daily substance use by detailed inquiry
from an interviewer and use of a calendar with salient
prompts to aid recall.
Where participants met DSM-IV abuse or depen-
dence criteria for more than one substance, the main
substance was identified as that perceived by the parti-
cipant to be most problematic or, if the person did not
make such a distinction, themost frequently used. Sub-
stance use was evaluated in terms of both the patient’s
main substance and all substances consumed by using
measures of frequency (percentage days abstinent) and
severity (percentage change from baseline in average
amount per using day), as calculated fromparticipants’
timeline followback reports. At each assessment point
patients were asked to report all substance use per day
during the previous 90 days, irrespective of specific use
at baseline. Alcoholic drinks were translated into stan-
dard UK units (1 unit=10 ml pure ethanol) and drugs
Table 1 | Baseline demographics and psychiatric and substance use history
Control (n=163) Therapy (n=164)
Age (mean (SD)) 38.3 (10.0) 37.4 (9.4)
Gender (n male (%)) 137 (84.0) 146 (89.0)
Current living arrangements
Alone 81 (49.7) 71 (43.3)
With family or partner 41 (25.2) 57 (34.8)
House share, hostel, or temporary 41 (25.2) 36 (22.0)
Ethnicity
White 131 (80.4) 135 (82.3)
Black 18 (11.0) 17 (10.4)
Asian 4 (2.5) 8 (4.9)
Other 10 (6.1) 4 (2.4)
Age on leaving education (mean (SD)) 16.2 (2.1) 16.0 (1.6)
Employment
Unemployed 150 (92.0) 153 (93.3)
Employed, retired, or student 13 (8.0) 11 (6.7)
History of psychosis (years; mean (SD)) 12.8 (9.8) 11.6 (8.7)
Case note diagnosis
Schizophrenia 134 (82.2) 133 (81.1)
Schizophreniform disorder 3 (1.8) 1 (0.6)
Schizoaffective disorder 14 (8.6) 13 (7.9)
Psychosis not otherwise specified 12 (7.4) 17 (10.4)
History in pre-baseline year
Admitted 32 (19.6) 46 (28.0)
Relapsed 54 (33.1) 68 (41.5)
Drug attitude inventory compliance rating 133 (81.6) 138 (84.1)
Usual care provided by assertive outreach and dual diagnosis
service rather than by community mental health team
13 (8.0) 11 (6.7)
History of substance use (years; mean (SD)) 14.5 (9.6) 13.1 (9.8)
Alcohol use disorders identification test* (0-40 scale; mean (SD)) 21.5 (7.8) 21.1 (7.6)
Drug abuse screening test† (0-20 scale; mean (SD)) 8.2 (4.2) 9.4 (4.4)
DSM-IV diagnosis (main substance)
Dependence 132 (81.0) 140 (85.4)
Abuse 31 (19.0) 24 (14.6)
Substance types with DSM-IV diagnosis‡
Alcohol only 80 (49.1) 77 (47.0)
Drug only 56 (34.4) 60 (36.6)
Alcohol and drug 27 (16.6) 27 (16.5)
Values are n (%) unless otherwise specified.
*Participants with main substance alcohol; scores >15 reflect “high problems.”
†Participants with main substance a drug; scores between 6 and 10 reflect “moderate problems.”
‡Meeting Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), diagnosis of
dependence on or abuse of drugs, alcohol, or both.
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were recorded by weight and cost or by number of
tablets and cost, as appropriate.
To provide collateral checks on participants’ self
reports, care coordinators completed abbreviated
timeline followback assessments (reports of patients’
substance use per week during the previous 90 days)
and the alcohol use scale and drug use scale of the clin-
ician rating scales38 at baseline and at 6, 12, 18, and
24 months. Additionally, we aimed to ask 25% of con-
senting participants to give hair samples that were later
analysed by a specialist hair analysis company (Tricho-
Tech Ltd, Abingdon, Oxfordshire) to detect the pre-
sence of illicit drug use.
Secondary outcomes: symptoms and functioning
The total score and scores on the positive, negative,
and general subscales of the positive and negative syn-
drome scale were used to assess symptoms of
psychosis.39 Participants’ functioning was assessed
using the total score and scores on the symptoms and
functioning subscales of the global assessment of
functioning.40 Occurrence (yes/no) of an episode of
deliberate self harm in the previous 12 months was
obtained via self report by using a brief structured
interview.
All trained assessors used the positive and negative
syndrome scale to rate 10 “gold standard” video
recorded interviews before starting trial assessments.
Mean intraclass correlation coefficients across all asses-
sors indicated excellent inter-rater reliability: positive
subscale 0.89; negative subscale 0.85; general subscale
0.88; and total score 0.86. Ratings were checked
throughout the trial by using a random sample of 24
recorded interviews with trial participants. Intraclass
correlation coefficients ranged from excellent to good
agreement: for the positive and negative syndrome
scale, positive subscale 0.76; negative subscale 0.72;
general subscale 0.71; total 0.70; and for the global
assessment of functioning 0.70.
Sample size and power
On the basis of our earlier study,10 we estimated that
60% of the control group would either die or be
admitted to hospital during the follow-up period, and
we allowed for 10% attrition owing to inadequate or
unavailable case notes. A sample size of 180 patients
in each group would have about 95% power to detect a
difference between the two groups with a significance
level of 0.05, assuming that the rate of admission or
death would be reduced from 60% to 40% in the treat-
ment arm. Thus we aimed to recruit 400 patients.
We revised this sample size to 320 in February 2006
because recruitment was slower than anticipated. This
number of patients would provide primary outcome
data on 140 participants per group, with about 90%
power to detect a reduction in the rate of admission or
death from 60% to 40%. We estimated that we would
also have secondary outcome data on 130 participants
per arm and thus have 80% power to detect an effect
size of 0.35 with a two sided significance level of 0.05.
Statistical analysis
Data were analysed according to the intention to treat
principle. All analyses to estimate treatment effects were
variations on an analysis of covariance that allowed for
location (NHS trust) and main substance used. The
Allocated to therapy (n=164):
 0-2 therapy sessions (n=15)
 3-10 sessions (n=25)
 11-20 sessions (n=57)
 21+ sessions (n=67)
Allocated to treatment as usual (n=163)
Potentially eligible and approached for screening (n=722)*
Screened for substance use (n=571)
Randomised (n=327)
Secondary outcomes analysed at 6 months
  (n=149)†
    Cumulative lost to follow-up (n=14):
      Died (n=2)
      Withdrawn (n=6)
      Unavailable (n=5)
      Refused (n=1)
Excluded (n=151):
  Refused when asked by care coordinator (n=85)
  Refused when asked by research assistant (n=66)
Did not meet substance use eligibility criteria (n=244)
Secondary outcomes analysed at 12 months
  (n=134)†
    Cumulative lost to follow-up (n=29):
      Died (n=5)
      Withdrawn (n=13)
      Unavailable (n=5)
      Refused (n=3)
      Part completed (n=3)
Secondary outcomes analysed at 18 months
  (n=129)†
    Cumulative lost to follow-up (n=34):
      Died (n=5)
      Withdrawn (n=20)
      Unavailable (n=5)
      Refused (n=3)
      Part completed (n=1)
Primary outcome analysed at 24 months (n=163)
Secondary outcome analysed at 24 months
  (n=117)†
    Cumulative lost to follow-up (n=46):
      Died (n=5)
      Withdrawn (n=31)
      Unavailable (n=9)
      Refused (n=0)
      Part completed (n=1)
Primary outcome analysed at 24 months (n=163)
  Misdiagnosis (n=1)‡
Secondary outcome analysed at 24 months
  (n=129)†
    Cumulative lost to follow-up (n=35):
      Died (n=2)
      Withdrawn (n=25)
      Unavailable (n=7)
      Refused (n=0)
      Part completed (n=0)
      Misdiagnosis (n=1)‡
Secondary outcomes analysed at 6 months
  (n=147)†
    Cumulative lost to follow-up (n=17):
      Died (n=1)
      Withdrawn (n=6)
      Unavailable (n=5)
      Refused (n=3)
      Part completed (n=1)
      Misdiagnosis (n=1)‡
Secondary outcomes analysed at 12 months
  (n=135)†
    Cumulative lost to follow-up (n=29):
      Died (n=2)
      Withdrawn (n=11)
      Unavailable (n=4)
      Refused (n=4)
      Part completed (n=7)
      Misdiagnosis (n=1)‡
Secondary outcomes analysed at 18 months
  (n=131)†
    Cumulative lost to follow-up (n=33):
      Died (n=2)
      Withdrawn (n=17)
      Unavailable (n=4)
      Refused (n=6)
      Part completed (n=3)
      Misdiagnosis (n=1)‡
Fig 1 | CONSORT diagram showing patient flow through the trial. *Identified by care coordinator
and psychiatric diagnosis confirmed from case notes. †Positive and negative syndrome scale
and timeline followback assessments completed. ‡One patient with a clinical diagnosis of
schizophrenia was randomly allocated to psychological therapy but subsequently received a
diagnosis of bipolar affective disorder and withdrew from the trial before receiving therapy
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exact form of the analysis depended on whether the data
were binary, ordinal, or quantitative. For secondary out-
comes, the baseline value for the relevant outcome mea-
sure was covaried where appropriate. Gender, service
type, and living circumstanceswere also includedas base-
linecovariatesbecause theywere foundpredictiveofattri-
tion in a preliminary analysis of missing secondary
outcome data. Implicit in these analyses was the assump-
tion that data were missing completely at random after
conditioning on all of the baseline covariates. Where
quantitative outcomes were positively skewed, standard
errors for parameters, and their confidence intervals and
P values, were obtained through the use of robust “sand-
wich” estimates.41
With the exception of the timeline followback, sec-
ondary outcomes were analysed separately for the two
assessment points (12 and 24 months). To reduce the
number of analyses and the likelihood of type 1 errors,
timeline followback variables were evaluated across
the four time points (6, 12, 18, and 24 months) by
using repeatedmeasures analysis, withmodels estimat-
ing treatment effects common to all time points. Quan-
titative outcomes (frequency of substance use) were
analysed using a random effects model. In order to
deal with their highly skewed distributions, timeline
followback variables assessing change from baseline
in average daily amount of substance use were re-
coded into five point ordinal severity scales, with
codes 1 and 2 corresponding to deterioration and 3-5
to improvement (1=more than 20% increase, 2=up to
20% increase, 3=39% to 0% reduction, 4=40% to 79%
reduction, and 5=80% to 100% reduction). Treatment
effects for these ordinal outcome scales were estimated
via a marginal ordinal regression model that allowed
for the covariates and for time as a within person effect,
with the participant as the clustering variable. Again,
robust “sandwich” estimators were used for the evalua-
tion of these treatment effects.
RESULTS
Participants
A total of 722 patients were referred to the trial: 151
declined to be screened for eligibility; 244 did notmeet
substance use criteria at screening; and 327 underwent
baseline assessment andwere randomised.Data on the
primary outcome were collected for 326 (99.7%) parti-
cipants. Key secondary outcomes (positive and nega-
tive syndrome scale and timeline followback) were
available for 269 (82.2%) participants at 12 months
and 246 (75.2%) participants at 24 months. Participant
flow through the trial is shown in figure 1.
Table 1 presents demographic information and psy-
chiatric and substance use history for patients allocated
to each trial arm. Participants had amean age of late 30s,
were predominantly male, and tended to be living on
theirownwithout a family orpartner.Theyhad long self
reported histories of both psychosis and substance use.
Baseline case note diagnoses are given in table 1. All
psychiatric diagnoses were re-assessed by chart review
at the end of the trial and 323 (98.8%) participants ful-
filled DSM-IV criteria for non-affective psychosis,
whereas four (1.2%) met criteria for affective psychosis.
Substance use at baseline is shown in table 2. Parti-
cipants reported alcohol and drug use on most days
(table 3) and their responses to the readiness to change
questionnaire (table 4) indicated that few people
entered the study at an action stage for reducing their
main substance. Table 5 shows symptomand function-
ing profiles at baseline. Mean general functioning was
low, with 96% of participants in the range from serious
impairments to inability to function in almost all areas
(global assessment of functioning scores 50 to 21).
Validity of patient timeline followback
Comparison of patient self reports with hair samples,
care coordinator reports (abbreviated timeline follow-
back and clinician rating scales), and baseline patient
alcohol use disorders identification test or drugmisuse
screening test indicated adequate concurrent validity.
At baseline, 241 participants (74%) gave consent for
a hair sample to be taken, 60 (25%) of whomwere ran-
domly selected. The refusal rate during assessments
was high (42%), and a third (34%) of patients had insuf-
ficient headhair, thus afterMarch 2007we approached
all patients who gave initial consent. In total, 61 parti-
cipants (19%) provided hair samples for at least one
time point.
Averaged across eight substances (cannabis, amphe-
tamine, heroin, cocaine, crack, ecstasy, methadone,
and benzodiazepines), the agreement between sub-
stances identified in hair samples and substances
reported by the participant on the timeline followback
was κ=0.67, the agreement for cannabis being κ=0.55.
The mean agreement between patient self reports and
care coordinator reports for seven substances (alcohol,
cannabis, amphetamine, heroin, cocaine, crack, and
ecstasy; methadone and benzodiazepines were
excluded owing to insufficient reports), averaged
across the five assessments was κ=0.62 (alcohol
κ=0.62; cannabis κ=0.70).
There were significant (P<0.01) associations
between patient and care coordinator timeline follow-
back reports, with intraclass correlation coefficients as
follows: percentage of days abstinent from main
Table 2 | Substance use at baseline
Control (n=163) Therapy (n=164)
Main substance
(n (%))
Any use (n
(%))
Main substance
(n (%))
Any use
(n (%))
Alcohol* 93 (57.1) 107 (65.6) 94 (57.3) 104 (63.4)
Cannabis 42 (25.8) 82 (50.3) 40 (24.4) 78 (47.6)
Cocaine 5 (3.1) 15 (9.2) 1 (0.6) 12 (7.3)
Ecstasy 0 (0.0) 12 (7.4) 1 (0.6) 5 (3.0)
Heroin 6 (3.7) 15 (9.2) 6 (3.7) 17 (10.4)
Amphetamines 8 (4.9) 17 (10.4) 11 (6.7) 27 (16.5)
Crack 8 (4.9) 13 (8.0) 9 (5.5) 22 (13.4)
Other 1 (0.6) 14 (8.6) 2 (1.2) 16 (9.8)
Polysubstance use† — 72 (44.2) — 70 (42.7)
*Alcohol use meeting Diagnostic and Statistical Manual of Mental Disorders, fourth edition, dependence or
abuse criteria.
†Two or more substances, including use of any illicit drug, alcohol above safe limits, or both.
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substance 0.67; percentage change in average daily
amount of main substance 0.39; units of alcohol 0.63;
and weight of cannabis 0.49. There were also signifi-
cant associations between care coordinator reports on
the alcohol use scale of the clinician rating scales and
percentage of days abstinent from main substance
(Spearman’s ρ=−0.40) and units of alcohol (ρ=0.50).
Care coordinator reports on the drug use scale were
significantly associated with the weight of cannabis
consumed (ρ=0.48) but not with days abstinent from
drug use (ρ=−0.17). Baseline self reported severity
measures (alcohol use disorders identification test or
drug misuse screening test) showed good association
with amounts of alcohol consumed (ρ=0.54) and can-
nabis use (ρ=0.39), but had weak and non-significant
associations with days abstinent (cannabis ρ=−0.11;
alcohol ρ=−0.13).
Treatment delivered and treatment fidelity
The mean number of sessions delivered to patients
who were allocated to psychological therapy was 16.7
(SD 8.3). The number of items rated as compliant on
the treatment fidelity scale ranged from 13/16 (81%) to
16/16 (100%) across the 40 sessions audiotaped ses-
sions rated.
Outcomes
Primary outcome
During the total 24month study period, therewere two
(1.2%) deaths among the 163 individuals in the therapy
group analysed and five (3.1%) deaths in the 163
patients in the control group. A higher proportion of
patients in the therapy group than in the control group
were admitted during follow-up (including those in
hospital at the point of follow-up; 22.1% (36/163) and
17.2% (28/163), respectively). Thus 23.3% (38/163) of
the therapy group and 20.2% (33/163) of the control
group reached the primary outcome criteria. This dif-
ference was non-significant (adjusted odds ratio 1.16,
95% confidence interval 0.68 to 1.99; P=0.579), with
the adjusted model predicting the primary outcome
for 22.2% of the therapy group and 19.7% of the con-
trol group.
Secondary outcomes: relapse and admissions
During the 24 month trial period, 39.1% (63/161) of
the therapy group and 37.9% (61/161) of the control
group experienced at least one relapse in psychotic
symptoms, a non-significant difference (adjusted OR
1.05, 95%CI 0.67 to 1.66; P=0.833). Descriptive statis-
tics for the number and duration of relapses and admis-
sions during the intervention and follow-up year are
provided in table 5. There were no significant differ-
ences between the therapy group and control group
on any of these outcomes.
Secondary outcomes: substance use
For percentage days abstinent from substance use
(table 3), there was no difference between the therapy
group and the control group for either main substance
(adjusted coefficient estimated using random effects
1.28, 95% CI −5.88 to 8.45; P=0.725) or all substances
(4.18, 95% CI −2.63 to 11.00; P=0.229). However, the
integrated therapy was found to have a statistically sig-
nificant effect on the amount of substance used per sub-
stance using day (table 6, fig 2) in terms of both main
substance (adjustedORestimatedusing ordinal regres-
sion 1.50, 95% CI 1.08 to 2.09; P=0.016) and all sub-
stances (1.48, 95% CI 1.07 to 2.05; P=0.017). Thus for
the therapy group, the odds of being in one of themore
abstinent groups versus one of the less abstinent groups
are 1.50 times higher than for the control group for
main substance (1.48 higher for all substances), given
the other variables in the model are held constant.
Table 6 shows that the proportion of participants
who had reduced their average daily intake of the
main substance since baseline was 20% greater (18%
for all substances) in the therapy group than in the con-
trol group (averaged across follow-up assessments).
Table 3 | Substance use: frequency of substance use (timeline followback) and inventory of
drug use consequences
Control Therapy
Total n Mean (SD) Total n Mean (SD)
Proportion of days abstinent from main substance (%)
Baseline 163 27.11 (27.32) 163 28.68 (27.27)
6 months 148 39.60 (38.31) 147 38.90 (36.40)
12 months 137 41.49 (37.29) 138 48.30 (37.82)
18 months 128 49.20 (38.68) 130 47.99 (39.45)
24 months 117 48.77 (39.69) 129 51.29 (39.80)
Proportion of days abstinent from all substances (%)
Baseline 160 22.72 (24.89) 163 25.81 (26.03)
6 months 148 30.06 (35.18) 147 34.27 (34.01)
12 months 136 34.51 (34.18) 137 40.24 (36.18)
18 months 127 38.47 (34.94) 129 38.17 (37.23)
24 months 117 37.18 (36.89) 130 44.25 (38.36)
Inventory of drug use consequences (0-45 scale)
Baseline 160 15.60 (11.28) 159 16.06 (10.24)
12 months 128 12.49 (11.08) 129 12.19 (11.23)
24 months 117 11.50 (11.93) 124 11.23 (11.23)
Table 4 | Substance use: readiness to change
Control Therapy
Total n n (%) Total n n (%)
Baseline
Pre-contemplative 162 40 (24.7) 163 43 (26.4)
Contemplative 162 71 (43.8) 163 80 (49.1)
Action 162 51 (31.5) 163 40 (24.5)
12 months
Pre-contemplative 134 37 (27.6) 139 23 (16.5)
Contemplative 134 47 (35.1) 139 47 (33.8)
Action 134 50 (37.3) 139 69 (49.6)
24 months
Pre-contemplative 118 27 (22.9) 126 30 (23.8)
Contemplative 118 40 (33.9) 126 51 (40.5)
Action 118 51 (43.2) 126 45 (35.7)
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Compared with controls, patients allocated to the inte-
grated therapy significantly increased their motivation
to reduce substances at 12 months (adjusted OR 2.05,
95%CI 1.26 to 3.31; P=0.004), although this significant
effect was not maintained at 24 months (0.78, 95% CI
0.48 to 1.28; P=0.320; table 4). For perceived conse-
quences of substance use, there were no differences
between the therapy group and the control group at
Table 5 | Mean (SD) scores and robust treatment effect estimates: positive and negative syndrome scale, global assessment
of functioning, and number and duration of admissions and relapses
Control Therapy Robust treatment effect estimates
n Mean (SD) n Mean (SD) Coefficient (95% CI) SE P value
Positive and negative syndrome scale*
Baseline — —
Positive 163 16.11 (5.50) 164 15.92 (5.16) — — —
Negative 163 13.44 (4.13) 164 14.49 (4.77) — — —
General 163 31.63 (7.53) 164 33.24 (8.01) — — —
Total 163 61.17 (13.25) 164 63.65 (14.26) — — —
12 months
Positive 137 14.59 (5.35) 137 14.62 (4.85) −0.01 (−1.00 to 0.99) 0.51 0.93
Negative 137 12.97 (4.08) 137 13.36 (4.65) −0.31 (−1.20 to 0.58) 0.45 0.49
General 137 27.74 (6.94) 137 29.85 (7.52) 0.85 (−0.60 to 2.30) 0.74 0.25
Total 137 55.30 (12.98) 137 57.82 (14.10) 0.27 (−2.31 to 2.86) 1.31 0.84
24 months
Positive 118 13.55 (5.22) 129 14.07 (5.38) 0.48 (−0.59 to 1.55) 0.54 0.37
Negative 118 12.46 (3.78) 129 12.62 (4.24) −0.29 (−1.19 to 0.61) 0.46 0.53
General 118 25.84 (6.44) 129 27.87 (7.80) 1.06 (−0.49 to 2.60) 0.78 0.18
Total 118 51.85 (11.57) 129 54.56 (14.70) 1.02 (−1.76 to 3.80) 1.41 0.47
Global assessment of functioning†
Baseline
Symptoms 160 40.22 (15.66) 163 39.32 (14.58) — — —
Disability 160 40.57 (9.58) 163 38.74 (7.19) — — —
Total 160 34.99 (10.10) 163 33.57 (7.59) — — —
12 months
Symptoms 134 41.87 (15.60) 135 41.06 (15.63) −0.69 (−2.31 to 2.86) 1.75 0.84
Disability 134 40.28 (8.56) 135 39.25 (8.96) −0.13 (−1.98 to 1.73) 1.67 0.89
Total 134 35.60 (9.36) 135 34.96 (9.46) −0.11 (−2.16 to 1.95) 1.04 0.92
24 months
Symptoms 115 44.46 (16.69) 119 42.92 (17.14) −1.43 (−5.48 to 2.62) 2.06 0.49
Disability 115 40.12 (11.51) 119 39.70 (9.61) 0.17 (−2.44 to 2.78) 1.32 0.90
Total 115 36.18 (10.27) 119 35.97 (10.93) 0.28 (−2.19 to 2.76) 1.26 0.82
Admissions in past 12 months
Number of admissions
Baseline 162 0.28 (0.63) 161 0.41 (0.82) — — —
12 months 162 0.22 (0.63) 163 0.22 (0.58) −0.01 (−0.14 to 0.12) 0.07 0.92
24 months 159 0.19 (0.49) 162 0.27 (0.65) 0.08 (−0.05 to 0.20) 0.06 0.22
Days admitted
Baseline 162 10.86 (32.43) 161 14.63 (37.30) — — —
12 months 162 10.35 (38.31) 163 12.64 (46.46) 2.32 (−7.16 to 11.80) 4.82 0.63
24 months 159 14.01 (52.21) 162 15.74 (44.59) 1.53 (−9.48 to 12.54) 5.60 0.78
Relapses in past 12 months
Number of relapses
Baseline 161 0.40 (0.60) 161 0.53 (0.71) — — —
12 months 161 0.27 (0.54) 161 0.30 (0.58) 0.02 (−0.10 to 0.15) 0.06 0.71
24 months 159 0.23 (0.45) 161 0.27 (0.55) 0.04 (−0.07 to 0.15) 0.06 0.45
Days in relapse
Baseline 161 48.96 (91.70) 161 62.04 (97.45) — — —
12 months 161 37.08 (76.84) 161 53.98 (95.56) 15.90 (−2.89 to 34.69) 9.55 0.10
24 months 159 40.23 (87.32) 161 40.48 (81.55) −1.86 (−20.58 to 16.85) 9.51 0.85
*The ranges of possible scores in the positive and negative syndrome scale are as follows: positive subscale 7-49; negative subscale 7-49; general
subscale 16-112; and total subscale 30-210.
†Global assessment of functioning symptoms subscale, disability subscale, and total score are all scored from 0-100.
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12months (adjusted coefficient −0.31, 95%CI −2.60 to
1.98; P=0.787) or at 24months (−0.65, 95%CI−3.21 to
1.92; P=0.620; table 3).
Secondary outcomes: symptoms and functioning
There were no statistically significant differences
between the two groups in terms of symptoms (positive
and negative syndrome scale) or functioning (global
assessment of functioning; table 5).At 12month assess-
ment, 14.4% (19/132) of participants in the therapy
group and 11.9% (16/135) in the control group
reported having deliberately self harmed during the
previous 12 month period. At 24 months, 9.5%
(12/126) of the therapy group and 6.8% (8/117) of the
control group reported self harm. The difference
between groups was not significant at either time
point (adjusted odds ratio at 12 months: 1.38, 95% CI
0.65 to 2.96, P=0.402; 24months: 1.48, 95%CI 0.56 to
3.91; P=0.433).
Safety of treatment and adverse events
There were seven participant deaths during the course
of the trial: two in the therapy group and five in the
control group. The causes were recorded as suicide,
non-dependent use of drugs, stroke, cancer, genetic
disorder, heart attack, and multiple physical condi-
tions. Four participants were admitted to a secure unit
during the trial, three ofwhomwere receiving the inter-
vention and one who was receiving treatment as usual.
Our independent data monitoring committee was
informed of all the above events and considered them
unrelated to the trial treatments.
Exploratory analyses of alcohol subgroup
Toexplorewhether the lack of effect of the therapywas
consistent for all substance use groups we examined
the largest subgroup—individuals who met only alco-
hol dependence or abuse criteria at baseline—and
compared it to the remaining participants. There was
a statistically significant treatment by subgroup inter-
action on the percentage of days abstinent from the
main substance (repeated measures analysis): the dif-
ference in means between the therapy group and the
control group for those individuals using alcohol only
(n=142) was 10.72% (95% CI 1.05 to 20.38; P=0.030)
and that for the remaining individuals (n=158) was
−7.42% (95% CI −17.55 to 2.72; P=0.152), the differ-
ence between the treatment effects (the interaction)
being 18.13% (95% CI 4.24 to 32.03; P=0.011). No
treatment by subgroup interactions were found either
on the primary outcome or on any other secondary
outcome.
DISCUSSION
Principal findings
This study shows that, when compared with treatment
as usual, integratedmotivational interviewing and cog-
nitive behavioural therapy for people with psychosis
and substance misuse does not improve outcome in
terms of deaths and hospitalisations, nor does it result
in improvements in other key clinical outcomes
including relapses, psychotic symptoms, functioning,
and self harm.
The integrated therapy did result in an increased
readiness to make changes in substance use by the
end of treatment, although this improved motivation
was reduced and no longer significant one year after
completion. However, this benefit was not sufficient
to influence clinical outcomes. The loss of improve-
ment in readiness to change scores by two year fol-
low-up would suggest that motivation to reduce
substance use waned in the year after therapy termi-
nated. Even a treatment period of a year may have
been too short for participating patients who had long
histories of heavy drug and alcohol misuse (often char-
acterised by polysubstance use), complex and long-
standing mental health problems, and low levels of
social functioning and support.
Patients in the therapy group were also more likely
to have reduced the amount of drink and drugs they
consumed when compared with people in the control
group. This better outcome was maintained over the
two year study and was evident for both patients’
main substance (as reported at start of study) and for
all other substances used over the course of the study.
At the same time, there was no effect of therapy on the
frequency of substance misuse.
For individuals with psychosis who reported only
alcohol abuse or dependence, the psychological ther-
apy had significant effects in terms of an increase in
days abstinent, which endured over the two year
follow-up. The exploratory analyses need to be viewed
with caution because they were unplanned and the
study was not designed to test differences in treatment
effects for subgroups. However, this differential effect
of the intervention according to substance type would
be consistent with outcome research in substance users
without mental health problems. Multiple psychoso-
cial treatments have been found to be efficacious for
alcohol problems in groups who do not have a dual
diagnosis,42 and brief motivational interventions have
been found to reduce alcohol consumption even in
groups not seeking treatment.43 On the other hand,
response rates for treatment for cannabis misuse,
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Fig 2 | Predicted probabilities of being in each of the five
change in substance use categories (change from baseline in
average daily amount of main substance) for therapy and
control groups, based on a repeated measures marginal
ordinal regression model that allowed for baseline covariates
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even for “motivated self referred treatment samples,”
have not been impressive.16 Additionally, there is con-
sistent evidence that outcomes for polysubstance users
(almost half the reported sample) are poorer.15
Comparison with other studies
A Cochrane review identified three studies that com-
pared cognitive behavioural therapy and motivational
interviewingwith standard care in people with psycho-
sis and substance misuse.6 Edwards and colleagues
found no effect of intervention in a sample of patients
whohad experienced a recent episodeof psychosis and
who also used cannabis.44 Baker et al found no effect of
integrated motivational interviewing and cognitive
behavioural therapyon substancemisuse or symptoms
but a significant improvement in functioning, as
assessed on the global assessment of functioning.45
Our previous study demonstrated significant bene-
fits of cognitive behavioural therapy and motivational
interviewing in terms of negative symptoms, function-
ing, and relapse rate at 12 month follow-up.10 19 One
factor that might explain these superior outcomes rela-
tive to the study reportedhere is that relapse rates in the
control group in the earlier study were much higher
(67% v 38% in the present study). Similarly, the fre-
quency of substance use in the control group showed
relatively little change from baseline in the earlier
study, but there were large decreases in the control
group in the current study. These better outcomes
with standard care in the study reported here might
reflect the widespread policy driven improvements in
care for dual diagnosis patients that have occurred in
the UK since 2001.7
Strengths and limitations of study
This is the largest randomised controlled trial to evalu-
ate an individual level treatment for psychosis and sub-
stance misuse. We had high rates of follow-up and low
refusal and dropout rates. These rates compare very
favourablywithdropout rates fromother treatment pro-
grammes for psychosis and substance misuse, which
report in excess of 50% of patients failing to engage.46
The large sample was drawn from both urban and
rural populations, and the sample characteristics seem
representative of patients with substance misuse and
psychosis presenting to mental health services,24 who
often have longstanding substance use, with frequent
misuse at moderate or severe levels, in the context of
low levels functioning and significant psychopathology.
Although we did not assess specific components of
standard care for each participant, we attempted to
reduce variation by including treatment locality as a
minimisation variable in the randomisation algorithm
and by providing guidelines on patient management.
The majority of those allocated to treatment partici-
pated in a substantial number of therapy sessions, and
therapists were well trained and supervised so we
achieved good treatment fidelity. The self reports of
patients regarding substance misuse were validated
by assessments from other sources, and we attained
good reliability on all observer rated outcomes. We
did not control for the additional therapist contact asso-
ciated with study participation because we sought only
to assess the effectiveness of the psychological therapy
relative to treatment as usual, and not to examine spe-
cific treatment effects.
For all the above reasons, we can have confidence
that the trial results give a reliable indication of the out-
comes from delivering integrated motivational inter-
viewing and cognitive behavioural therapy by trained
therapists to people with a diagnosis of psychosis and
moderate to heavy use of alcohol, illicit drugs, or both.
Conclusions and further research
Weconclude that integratedmotivational interviewing
and cognitive behavioural therapy for people with a
Table 6 | Ranked change scores of substance use at the four follow-up assessments (change from baseline in average amount per substance using day)
Control Therapy Increase in
probability of
improvement in
therapy group*n
Abstinent
or near
abstinent
Large
decrease
Small
decrease
Small
increase
Large
increase n
Abstinent or
near abstinent
Large
decrease
Small
decrease
Small
increase
Large
increase
Main substance
6 months 143 12 (8.4) 24 (16.8) 42 (29.4) 16 (11.2) 49 (34.3) 142 13 (9.2) 26 (18.3) 49 (34.5) 21 (14.8) 33 (23.2) 14%
12 months 132 13 (9.8) 23 (17.4) 32 (24.2) 19 (14.4) 45 (34.1) 134 20 (14.9) 31 (23.1) 38 (28.4) 13 (9.7) 32 (23.9) 29%
18 months 125 22 (17.6) 19 (15.2) 30 (24.0) 11 (8.8) 43 (34.4) 125 26 (20.8) 28 (22.4) 34 (27.2) 6 (4.8) 31 (24.8) 24%
24 months 113 20 (17.7) 20 (17.7) 23 (20.4) 12 (10.6) 38 (33.6) 125 27 (21.6) 20 (16.0) 32 (25.6) 16 (12.8) 30 (24.0) 13%
Average 20%
All substances
6 months 148 8 (5.4) 21 (14.2) 43 (29.1) 21 (14.2) 55 (37.2) 143 8 (5.6) 21 (14.7) 47 (32.9) 27 (18.9) 40 (28.0) 9%
12 months 136 9 (6.6) 19 (14.0) 34 (25.0) 23 (16.9) 51 (37.5) 137 15 (10.9) 30 (21.9) 36 (26.3) 20 (14.6) 36 (26.3) 30%
18 months 128 16 (12.5) 20 (15.6) 31 (24.2) 14 (10.9) 47 (36.7) 127 18 (14.2) 25 (19.7) 39 (30.7) 9 (7.1) 36 (28.3) 23%
24 months 115 11 (9.6) 22 (19.1) 26 (22.6) 9 (7.8) 47 (40.9) 127 17 (13.4) 21 (16.5) 33 (26.0) 20 (15.7) 36 (28.3) 9%
Average 18%
All values are n (%). Abstinent or near abstinent: −100% to −80% change from baseline; Large decrease: −79% to −40% change from baseline; Small decrease: −39% to 0% change from
baseline; Small increase: +1% to +20% change from baseline; Large increase: more than 20% change from baseline.
*Percentage increase in the proportion of participants who reduced substance use (“abstinent or near abstinent,” “large decrease,” and “small decrease” categories) in therapy group
compared with controls.
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diagnosis of psychosis and substance misuse does not
improveoutcome in terms of hospitalisation, symptom
outcomes, or functioning.Up to 26 sessions of the ther-
apy over one year was successful in engaging patients
in treatment and did improve patients’ motivation to
make changes in their substance use. Motivation for
changewaned after the treatment period finished, how-
ever, but there was an improvement in the amount of
substance used per day that was maintained over two
years’ assessment. Although the subgroup findings
derived from exploratory analyses should be inter-
preted with caution, they indicate that the treatment
may be more effective at reducing the substance use
in individuals who use alcohol only than in individuals
who use illicit drugs or both drugs and alcohol.
More research is needed as to how the limited bene-
fits seen in this study can be extended and maintained,
and whether people with severe mental health pro-
blems may require different treatments according to
the type substances they use. Meanwhile, clinicians
should be aware that although motivational inter-
viewing and cognitive behavioural therapy may facil-
itate engaging patients in treatment—increasing their
motivation for change and reducing their substance
use—it is not clear how best to improve clinical out-
comes for this group.
We thank the patients who participated in the study and all the staff who
facilitated recruitment. We are also grateful to all the collaborating NHS
trusts and to all the research assistants. TW acknowledges some
additional funding provided by National Institute for Health Research
(NIHR) Biomedical Research Centre for Mental Health at the South
London and Maudsley NHS Foundation Trust and the Institute of
Psychiatry, Kings College London. All authors acknowledge the support of
the NIHR Mental Health Research Network.
Contributors:All authors were involved in the design of the study and the
ongoing management of the trial, and contributed to drafts of this report.
CB, the principal investigator, conceived of the study, prepared the
protocol, contributed to the training and supervision of the therapists and
supervision of the researchers, had overall responsibility for the day to
day running of the study, interpreted the data, and took the lead on
writing this report. She is the guarantor for the study. GH, NT, TW, CS, JM,
and PC participated in preparation of the treatment protocol and the
training and supervision of the therapists. JM and PC were also
responsible for training and supervising staff in administration of
substance use measures. TW managed the London site. GH, SL, and TC
trained the researchers in the psychiatric interviews, supervised and
monitored standards of psychiatric interviewing and assessment
throughout the trial. SL and TC also advised on diagnostic ratings and
exclusions. RB was the trial manager. She supervised and coordinated
recruitment, contributed to training of research staff, and was responsible
for staff management and overall coordination of the study. EE replaced
RB for the latter part of the study. GD was the trial statistician. He advised
on randomisation and all statistical aspects of the trial, developed the
analysis plan, and performed the statistical analyses. LD was the trial
health economist.
Funding: The study was sponsored by the University of Manchester and
funded by the UK Medical Research Council (grant no: GO200471) and
the Department of Health. The sponsor and the funder of the study had
no role in the study design, the data collection, analysis, and
interpretation, or the reporting of this work, or the decision to submit the
work for publication. All authors are independent of the funding source.
All authors had full access to all study data.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: no support from any
organisation for the submitted work; no financial relationships with any
organisations that might have an interest in the submitted work in the
previous 3 years; no other relationships or activities that could appear to
have influenced the submitted work.
Ethical approval: Ethical approval was obtained from the Cambridgeshire
4 research ethics committee (formerly the eastern multicentre research
ethics committee; reference 03/5/045). All participants gave written
informed consent before taking part.
Data sharing:We will be happy to make our dataset available to
researchers once we have finished reporting our findings. Please contact
the corresponding author at christine.barrowclough@manchester.ac.uk.
1 Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al.
Comorbidity of mental disorders with alcohol and other drug abuse:
results from the Epidemiologic Catchment Area (ECA) Study. JAMA
1990;264:2511-8.
2 GrahamHL, Copello A, BirchwoodMJ,Maslin J, McGovern D, Orford J,
et al. The combined psychosis and substance use (COMPASS)
programme: an integrated, shared care approach. In: Graham HL,
Copello A, Birchwood MJ, Mueser KT, eds. Substance misuse in
psychosis: approaches to treatment and service delivery. John Wiley
& Sons, 2003:106-20.
3 Weaver T, Rutter D, Madden P, Ward J, Stimson G, Renton A. Results
of a screening survey for co-morbid substance misuse amongst
patients in treatment for psychotic disorders: prevalence and service
needs in an inner London borough. Soc Psychiatry Psychiatr
Epidemiol 2001;36:399-406.
4 Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in
schizophrenic patients: clinical correlates and reasons for use. Am J
Psychiatry 1991;148:224-30.
5 Maslin J. Substance misuse in psychosis: contextual issues. In:
Graham HL, Copello A, Birchwood MJ, Mueser KT, eds. Substance
misuse in psychosis: approaches to treatment and service delivery.
John Wiley & Sons, 2003:3-23.
6 Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G. Psychosocial
interventions for people with both severe mental illness and
substance misuse. Cochrane Database Syst Rev 2008;1:CD001088.
7 Department of Health. Mental health policy implementation guide:
dual diagnosis good practice guide. DH, 2002.
8 Ziedonis DM, SmelsonD, Rosenthal RN, Batki SL, Green AL, Henry RJ,
et al. Improving the care of individuals with schizophrenia and
substance use disorders: consensus recommendations. J Psychiatr
Pract 2005;11:315-406.
9 Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al.
Evaluation of a motivational interview for substance use within
psychiatric in-patient services. Addiction 2002;97:1329-37.
10 Barrowclough C, Haddock G, Tarrier N, Lewis SW,Moring J, O’Brien R,
et al. Randomised controlled trial of cognitive behavioural therapy
plusmotivational intervention for schizophrenia and substance use.
Am J Psychiatry 2001;158:1706-13.
11 MillerWR, Rollnick S.Motivational interviewing: preparing people for
change. 2nd ed. Guilford Press, 2002.
12 Martins RK, McNeil DW. Review of motivational interviewing in
promoting health behaviours. Clin Psychol Rev 2010;29;283-93.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Alcohol and drug misuse in people with psychosis is common, and this comorbidity is
associated with many illness complications
There is no compelling evidence to support any one psychosocial treatment for this patient
group
Limited evidence indicates that integrated motivational interviewing and cognitive
behavioural therapy might be helpful
Studies of integrated therapy in patients with psychosis have had recruitment and retention
problems
WHAT THIS STUDY ADDS
Integrated motivational interviewing and cognitive behavioural therapy delivered over one
year by trained therapists did not produce improvement in clinical outcomes for people with
psychosis and substance misuse
The therapy group had improved outcomes in terms of the amount of substances consumed
that were sustained over 24 months
Integrated therapy was associated with good engagement with and retention in treatment
Integrated therapy might have more effect on people who misuse alcohol than on those who
misuse drugs
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 11 of 12
13 Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev
Clin Psychol 2005;1;91-111.
14 Stewart SH, Conrod PJ. Introduction to the special issue on state-of-
the-art cognitive-behavioral interventions for substance use
disorders. J Cogn Psychother 2005;19:195-8.
15 Dutra L, StathopouluG,BasdenSL, Leyro TM,PowersMB,OttoMW.A
meta-analytic reviewof psychosocial interventions for substanceuse
disorders. Am J Psychiatry 2008;165:179-87.
16 Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic
interventions for cannabis abuse and/or dependence in outpatient
settings. Cochrane Database Syst Rev 2006;3:CD005336.
17 Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behaviour therapy for
schizophrenia: effect sizes, clinical models, and methodological
rigor. Schizophr Bull 2008;34:523-37.
18 National Institute for Health and Clinical Excellence. Schizophrenia:
core interventions in the treatment and management of
schizophrenia in adults in primary and secondary care (update).
NICE, 2009.
19 Haddock G, Barrowclough C, Tarrier N, Moring J, O’Brien R,
Schofield N, et al. Cognitive-behavioural therapy and motivational
intervention for schizophrenia and substance misuse: 18 month
outcomes of a randomised controlled trial. Br J Psychiatry
2003;183:418-26.
20 Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the
CONSORT statement to randomized trials of nonpharmacologic
treatment: explanation and elaboration. Ann Intern Med
2008;148:295-309.
21 Schulz K, Altman DG, Moher D, for the CONSORT Group. CONSORT
2010 statement: updated guidelines for reporting parallel group
randomised trials. BMJ 2010;340:c332.
22 Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC,
Devereaux PJ, et al. CONSORT 2010 explanation and elaboration:
updated guidelines for reporting parallel group randomised trials.
BMJ 2010;340:c869.
23 First MB, Spitzer RL, GibbonM, Williams JBW. Structured clinical
interview for DSM-IV axis 1 disorders—clinician version (SCID-CV).
American Psychiatric Press, 1997.
24 Barrowclough C, Haddock G, Beardmore R, Conrod P, Craig T,
Davies L, et al. Evaluating integrated MI and CBT for people with
psychosis and substancemisuse: recruitment, retention and sample
characteristics of the MIDAS trial. Addict Behav 2009;34:859-66.
25 Haddock G, Beardmore R, Earnshaw P, Fitzsimmons M, Nothard S,
Butler R, et al. Assessing fidelity for integrated motivational
interviewing and CBT therapy for psychosis and substance use: the
MI-CTS fidelity scale. J Ment Health (submitted 2010).
26 Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M.
Development of the Alcohol Use Identification Test (AUDIT): WHO
collaborative project on early detection of persons with harmful
alcohol consumption-II. Addiction 1993;88:791-804.
27 Babor T, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol
use disorders identification test: guidelines for use in primary care.
2nd ed. World Health Organization, 2001.
28 Skinner HA. The drug abuse screening test. Addict Behav
1982;7:363-71.
29 Alexander D, Leung P. The Marijuana Screening Inventory (MSI-X):
concurrent, convergent and discriminant validity with multiple
measures. Am J Drug Alcohol Abuse 2006;32:351-78.
30 Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of
drug compliance in schizophrenics: reliability and discriminative
validity. Psychol Med 1983;13:177-83.
31 Cicchetti D. Guidelines, criteria and rules of thumb for evaluating
normed and standardized assessment instruments in psychology.
Psychol Assess 1994;6:284-90.
32 Rollnick S, Heather N, Gold R, Hall W. Development of a short
‘readiness to change’ questionnaire for use in brief opportunistic
interventions amongexcessivedrinkers.Br J Addict1992;87:743-54.
33 Blanchard KA, Morgenstern J, Morgan TJ, Labouvie EW, Bux DA.
Assessing consequences of substance use: psychometric properties
of the Inventory of Drug Use Consequences. Psychol Addict Behav
2003;17:328-31.
34 Sobell LC,SobellMB. Timeline followback: a technique for assessing
self-reported alcohol consumption. In: Litten RZ, Allen JP, eds.
Measuring alcohol consumption: psychosocial and biochemical
methods. Humana Press Inc, 1992:41-72.
35 Carey KB. Reliability and validity of the time-line follow-back
interview among psychiatric outpatients: a preliminary report.
Psychol Addict Behav 1997;11:26-33.
36 Carey KB, Carey MP, Maisto SA, Henson JM. Temporal stability of the
timeline follow-back interview for alcohol and drug use with
psychiatric outpatients. J Stud Alcohol 2004;65:774-81.
37 Stasiewicz P, Vincent PC, Bradizza CM, Connors GJ, Maisto SA,
Mercer ND. Factors affecting agreement between severelymentally ill
alcohol abusers’ and collaterals’ reports of alcohol and other
substance use. Psychol Addict Behav 2008;22:78-87.
38 Drake RE, Mueser KT, McHugo GJ. Clinician rating scales: alcohol use
scale (AUS), drug use scale (DUS), and substance abuse treatment
scale (SATS). In: Sederer LI, Dickey B, eds.Outcomes assessment in
clinical practice. Williams &Wilkins, 1996:113-6.
39 Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
40 American Psychiatric Association. Diagnostic and statistical manual
of mental disorders (DSM-IV). 4th ed. American Psychiatric
Association, 1994.
41 White H. Maximum likelihood estimation of misspecified models.
Econometrica 1982;50:1-25.
42 Miller WR,Wilbourne PL. Mesa Grande: amethodological analysis of
clinical trials of treatments for alcohol use disorders. Addiction
2002;97:265-77.
43 Kaner EF, Dickinson HO, Beyer FR, Campbell F, Schlesinger C,
Heather N, et al. Effectiveness of brief alcohol interventions in
primary care populations. Cochrane Database Syst Rev
2007;2:CD004148.
44 Edwards J, Elkins K, Hinton M, Harrigan S, Donovan K,
Athanasopoulos O, et al. Randomised controlled trial of a cannabis-
focused intervention for young people with first-episode psychosis.
Acta Psychiatr Scand 2006;114:109-17.
45 Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ.
Cognitive-behavioural therapy for substance use disorders in people
with psychotic disorders: randomised controlled trial. Br J Psychiatry
2006;188:439-48.
46 Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized
clinical trial of a new behavioural treatment for drug abuse in people
with severe and persistent mental illness. Arch Gen Psychiatry
2006;63:426-32.
Accepted: 16 September 2010
RESEARCH
page 12 of 12 BMJ | ONLINE FIRST | bmj.com
